The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Background. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is currently considered as the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, three-year progression-free survival (PFS) and overall survival (OS) rates rema...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.30-31
Hauptverfasser:	Thieblemont, Catherine, Chartier, Loïc, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F, Vercellino, Laetitia, Zaucha, Jan, Patrocinio Carvalho, Inês, Maria, Gomes da Silva, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Rene-Olivier, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, George, Dunn, Joel, Cottereau, Anne Ségolène, Schmitz, Christine, Paulson, Joseph N., Nielsen, Tina G, Meignan, Michel
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!